A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

Summary

This open-label, single-dose, parallel group study will assess the pharmacokinetics and safety of RO4917838 in healthy volunteers and patients with mild, moderate or severe chronic hepatic impairment. Patients and healthy volunteers will receive a single oral dose of RO4917838.

Timeline

Start

2011-06

Primary completion

2011-10

Completion

2011-10

Drugs

Indications

No indication recorded.